N-acethyl-cysteine reduces the occurrence of contrast-induced acute kidney injury in patients with renal dysfunction: A single-center randomized controlled trial

Clinical and Experimental Nephrology

Volumn 17, Issue 3, 2013, Pages 396-404

  Heguilén, Ricardo M ^a   Liste, Amador A ^a   Payaslian, Miguel ^a   Ortemberg, Martin Gabriel ^a   Albarracín, Lautaro Martin ^a   Bernasconi, Amelia Rita ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Acute kidney injury; Bicarbonate; Contrast media; N acethyl cysteine

Indexed keywords

ACETYLCYSTEINE; BICARBONATE; CREATININE; IOVERSOL; POTASSIUM; SODIUM; URIC ACID;

ACUTE HEART INFARCTION; ADULT; AGED; ANAMNESIS; ARTICLE; CHEMOPROPHYLAXIS; COMBINATION CHEMOTHERAPY; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SODIUM BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ACETYLCYSTEINE; ACUTE KIDNEY INJURY; ADULT; AGED; CONTRAST MEDIA; CREATININE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMA SUBSTITUTES; RENAL INSUFFICIENCY; SODIUM BICARBONATE; SODIUM CHLORIDE; TRIIODOBENZOIC ACIDS;

EID: 84879415514     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-012-0722-3     Document Type: Article

References (60)

1. Briguori C, Tavano D, Colombo A. Contrast agent-associated nephrotoxicity. Prog Cardiovasc Dis. 2003;45:493-503.
2. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368-75.
3. Castini D, Lucreziotti S, Bosotti L, et al. Prevention of contrast-induced nephropathy: a single center randomized study. Clin Cardiol. 2010;33(3):63-8.
4. Wong GTC, Irwin MG. Contrast-induced nephropathy. Br J Anaesth. 2007;99(4):474-83.
5. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005;172(11):1461- 71.
6. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med. 1989;320:143-9.
7. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348(6):491-9.
8. Kuhn MJ, Chen N, Sahani DV, et al. The PREDICT Study: a randomized double-blind comparison of contrast-induced nephropathy after low or isoosmolar contrast agent exposure. AJR. 2008;191:151-7.
9. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med. 2003;349:1333-40.
10. Baker CSR, Baker LRI. Prevention of contrast nephropathy after cardiac catheterization. Heart. 2001;85:361-2.
11. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331(21):1416-20.
12. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. Kidney Int. 1995;47(1):254-61.
13. Stone GE, McCullough PA, W for the CONTRAST Investigators. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA. 2003;290(17):2284-91.
14. Bakris GL, Lass NA, Glock D. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: a role for dopamine-1 receptors. Kidney Int. 1999;56:206-10.
15. Bakris G, Burnett J. A role for calcium in radiocontrast induced reductions in renal hemodynamics. Kidney Int. 1985;27(2):465-8.
16. Kapoor A, Kumar S, Gulati S, Gambhir S, Sethi R, Sinha N. The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrol Dial Transpl. 2002;17(11):1936-41.
17. Huber W, Ilgmann K, Page M, et al. Effect of theophylline on contrast material-induced nephropathy in patients with chronic renal insufficiency: controlled randomized, double-blinded study. Radiology. 2002;223:772-9.
18. Safirstein R, Andrade L, Vieira JM. N-acetylcysteine and nephrotoxic effects of RC agents: a new use for an old drug. N Engl J Med. 2000;343:210-2.
19. Teruel JL, Maracen R, Herrero JA, Ortuno FJ. An easy and effective procedure to prevent radiocontrast nephrotoxicity in high-risk patients [letter]. Nephron. 1989;51(2):282.
20. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Int Med. 2008;148:284-94.
21. Heyman SN, Rosen S, Brezis M. Radiocontrast nephropathy: a paradigm for the synergism between toxic and hypoxic insults in the kidney. Exp Nephrol. 1994;2:153-7.
22. Heyman SN, Brezis M, Epstein FH, Spokes K, Silva P, Rosen S. Early renal medullary hypoxic injury from radiocontrast and indomethacin. Kidney Int. 1991;40:632-42.
23. Heyman SN, Brezis M, Reubinoff CA, et al. Acute renal failure with selective medullary injury in the rat. J Clin Invest. 1988;82:401-12.
24. Brezis M, Rosen S. Hypoxia of the renal medulla - its implications for disease. N Engl J Med. 1995;332(10):647-55.
25. Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Contrast media-associated nephrotoxicity. Semin Nephrol. 1997;17(1):15-26.
26. Pflueger A, Larson TS, Nath KA, King BF, Gross JM, Knox FG. Role of adenosine in contrast media-induced acute renal failure in diabetes mellitus. Mayo Clin Proc. 2000;75:1275-83.
27. Bakris GL, Lass N, Gaber AO, Jones J, Burnett J Jr. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol. 1990;258:F115-20.
28. Bakris GL, Gabaer AO, Jones JD. Oxygen free radical involvement in urinary Tamm-Horsfall protein excretion after intrarenal injection of contrast medium. Radiology. 1990;175:57-60.
29. Katholi R, Woods T Jr, Taylor G, et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis. 1998;32(1):64-71.
30. Lee HC, Sheu SH, Yen HW, Lai WT, Chang JG. JNK/ATF2 pathway is involved in iodinated contrast media-induced apoptosis. Am J Nephrol. 2010;31:125-33.
31. Tepel M, Van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by N-acetylcysteine. N Engl J Med. 2000;343(3):180-4.
32. Skyu KG, Cheng JJ, Kuan P. N-acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002;40:1383-8.
33. Kay J, Chow WH, Chan TM, et al. N-acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003;289(5):553-8.
34. Baker CS, Wragg A, Kuman S, De Palma R, Baker L, Knight C. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003;41(12):2114-8.
35. Birck R, Krzossk S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362:598-603.
36. Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004;110(18):2837-42.
37. Alpern RJ. Renal acidification mechanisms. In: Brenner BM, editor. The kidney. 6th ed. Philadelphia, PA: WB Saunders; 2000. p. 455-519.
38. Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in human diseases: an overview. Methods Enzymol. 1990;186:1-85.
39. Cohen G. The Fenton reaction. In: Greenwald RA, editor. CRC handbook of methods for oxygen radical research. Boca Raton, FL: CRC Press Inc; 1985. p. 55-64.
40. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate. A randomized controlled trial. JAMA. 2004;291(19):2328-34.
41. Gomes VO, Poli de Figueredo CE, Caramori P, et al. N-acethylcysteine does not prevent contrast induced nephropathy after cardiac catheterization with an ionic low osmolality contrast medium: a multicenter clinical trial. Heart. 2005;91:774-8.
42. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39:930-6.
43. McCullough PA, Adam A, Becker CR, et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Med. 2006; 98 Suppl 6A:5K-13K.
44. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393-9.
45. Goldenberg I, Shechter M, Matetzky S, et al. Oral acethylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J. 2004;25:212-8.
46. Maioli M, Toso A, Leoncini M, et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol. 2008;52:599-604.
47. Navaneethan SD, Singh S, Appasamy S, Wing RE, Sehgai AR. Sodium bicarbonate therapy for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2009;53(4):617-27.
48. Liu R, Nair D, Ix J, Moore DH, Bent S. N-acethylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J Gen Intern Med. 2005;20:193-200.
49. Marenzi G, Assanelli E, Marana I. N-acethylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773-82.
50. Calvin AD, Misra S, Pflueger A. Contrast-induced acute kidney injury and diabetic nephropathy. Nat Rev Nephrol. 2010;6(11):679-88.
51. ACT Investigators. Acethylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography. Main results from the randomized acethylcysteine for contrast-induced nephropathy trial (ACT). Circulation. 2011;124:1250-9.
52. Kunadian V, Zaman A, Spyridopoulos I, Qiu W. Sodium bicarbonate for the prevention of contrast induced nephropathy: a meta-analysis of published clinical trials. Eur J Radiol. 2010; doi: 10.1016/j.ejrad.2009.12.015.
53. Novikov M, Molitoris B, Campos S, et al. Renoprotective properties of acetazolamide in a rat model of contrast media induced renal failure (abstract). J Am Soc Nephrol. 2003;14:345A.
54. Hoste EA, De Waele JJ, Gevaert SA, Uchino S, Kellum JA. Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis. Nephrol Dial Transpl. 2010;25(3):747-58.
55. Zoungas S, Nimomiya T, Huxley R, et al. Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Int Med. 2009;11(9):631-8.
56. From AM, Bartholmai BJ, Williams AW, Cha SS, Pfluger A, McDonald FS. Sodium bicarbonate is associated with an increased incidence of contrast nephropathy. A retrospective cohort study of 7977 patients at Mayo Clinic. Clin J Am Soc Nephrol. 2008;3(1):10-8.
57. 2/bicarbonate and hydrogen peroxide. Free Radic Biol Med. 2003;35(12):1538-50.
58. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14(10):2534-43.
59. Haase M, Bellomo R, Decarajan P, Schlattmann P, Haase-Fielitz A, the NGAL Meta-Analysis Investigator Group. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009;54(6):1012-24.
60. Soni S, Ronco C, Katz N, Cruz D. Early diagnosis of acute kidney injury: the promise of novel biomarkers. Blood Purify. 2009;28:165-74.